

TECHNOLOGY-DRIVEN

The Venner PneuX™ System

- a major development in the prevention of Ventilator-Associated Pneumonia (VAP)

Aspiration -Why take the risk?

The **Venner PneuXTM** System has the ONLY endotracheal tube (ETT) to consistently prevent ANY aspiration past the cuff when directly compared to other ETTs.1

The **Venner PneuX**TM System has been recognised as providing an evidence-based solution to minimising VAP.



Leakage of ETTs after I hour of placing in the 'model trachea'

Each cuff was inflated to the correct pressure according to the manufacturer's instructions using a hand-held manometer. If continuous cuff pressure monitors were recommended, these were used to maintain cuff inflation during experiments.














2. KimVent™ MICROCUFF™ Subglottic Suctioning Endotracheal Tube

- 3. Mallinckrodt™ Hi-Lo Oral Endotracheal Tube, Lanz System
- **4.** Mallinckrodt[™] SealGuard[™] Evac Endotracheal Tube
- 5. Portex Soft Seal® Cuff Tracheal Tube
- 6. Portex SACETT™ Suction Above ET Cuff
- 7. Teleflex ISIS® HVT™
- 8. Venner PneuX™ ETT

Photographs taken as part of the Mariyaselvam et al study(1)









VAP - the most common nosocomial infection in critically ill patients²

- Up to 20% of patients receiving >48 hours of mechanical ventilation will develop VAP²
- Patients with VAP have significantly longer intensive care unit lengths of stay² (average of 6.1 days)
- The incidence of VAP increases with the duration of mechanical ventilation. VAP causes longer ICU and hospital stay, higher mortality, and higher hospital costs (up to \$40,000/case (approximately $£24,000))^3$
- Critically ill patients with VAP are twice as likely to die compared to similar patients without VAP²
- Tubes with single subglottic drainage ports frequently fail (48%) incidence)4, and this failure is associated with an increased incidence of VAP5.

Hourly Subglottic Secretion Drainage (SSD) can reduce the incidence of VAP by up to 64%6.

	Control group	SSD group	p-value
VAP	22.1%	7.9%	0.001

The Venner PneuX™ System Multifactorial approach to the prevention of VAP

 Prevents pulmonary aspiration - whilst minimising the risk of mucosal injury

 Permits intermittent subglottic secretion drainage three subglottic ports

Protects the tracheal wall - the Venner PneuX TSM™ maintains a constant cuff pressure preventing aspiration

Specifically designed for atraumatic insertion with low-volume, low-pressure (LVLP) cuff - flexible silicone/wire construction which conforms to the airway





Features of the Venner PneuX™ System

Partnered with the Venner PneuX TSM™ designed exclusively for use with the Venner PneuX™ETT and the Venner PneuX™TT maintains a constant cuff pressure, minimising bacterial leakage⁷ and preventing aspiration¹.

A LVLP cuff with no folds, designed such that the tracheal wall pressure is kept at a continuous 30cm H₂O pressure, preventing aspiration8 whilst minimising the risk of mucosal injury associated with high-pressure cuffs^{1,8}.

Pulmonary aspiration can be prevented by using a lowvolume, low-pressure (LVLP) tracheal tube cuff9. 89% of patients have been shown to aspirate stomach contents^{1,9,10}.

Protects the tracheal wall and prevents aspiration.

Three subglottic ports remove secretions intermittently from the subglottic space.

A 'boat tip' that minimises forces when intubation is performed in combination with a bougie, exchanger, fiberoptic bronchoscope or stylet and which is designed to lie straight and not push forwards into the tracheal wall.

Flexible silicone/wire construction conforms to the airway, yet with strength against kinking.

Medical grade non-stick lining - inhibits the adhesion of biological materials. Bronchoscopes and suction catheters can normally pass without need for additional lubrication, thereby reducing the forces on the delicate laryngeal structures 12.

- 1. Mariyaselyam et al. BMC Anesthsiology 2017:17:36.
- 2. Safdar N et al. Crit Care Med 2005;33(10):2184-2193.
- 3. Gentile MA et al. Respiratory Care 2010;55(2):184-196.
- 4. Dragoumanis CK et al. Anesth Analg 2007;105(4):1083-1085.
- 5. Rello J et al. Am J Respir Crit Care Med 1996;154(1):111-115.
- 6. Lorente L et al. Am J Respir Crit Care Med 2007;176:1079-1083. 7. Mariyaselyam et al. Intensive Care Medicine Experimental 2015. 3(Suppl 1):A382.
- 8. Gopal S et al. J Hosp Infection 2017,95:81-86.
- 9. Young PJ et al. Crit Care Med 2006;34(3):632-639
- 10. Metheny NA et al. Crit Care Med 2006;34(4):1007-1015.
- 11. Greer JR et al. Anesthesiology 2001;94(5):729-731.
- 12. Steen JA et al. Crit Care Med 1982:10(3):186-189.





Please contact us to arrange a demonstration – info@qualitechhealthcare.co.uk